Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00570323 · ClinicalTrials.gov registry record · Phase 2
Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer
A Phase 2 study, sponsored by Mothaffar Rimawi.
- Completed
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
NCT00570323: Completed Phase 2 study, sponsored by Mothaffar Rimawi.
NCT00570323 is a Phase 2 study that has completed, run by Mothaffar Rimawi. The registered enrollment target is 72 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00570323, a Phase 2 study, has completed, sponsored by Mothaffar Rimawi.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
Study Summary
Over the last 3 decades, a steady shift has occurred in the management of breast cancer. Because it was traditionally viewed as a local disease, many advocated the use of radical surgery to achieve maximum survival benefit. This view has been slowly replaced by a broader biologic view that recognizes the often systemic nature of breast cancer, even when it appears to be localized to the breast. Results from randomized clinical trials have demonstrated that less extensive surgery, or lumpectomy plus radiation therapy, are optimal for local management of early breast cancer. In addition to the less radical approach to surgical treatment of breast cancer, other randomized clinical trials have established the value of postoperative systemic therapy in improving overall survival by eradicating micrometastatic disease, the major cause of mortality from breast cancer. Despite the well-documented benefits of adjuvant systemic therapy, it is not effective in preventing death from breast cancer in all patients who are candidates for such treatment. The worth of such therapy can only be judged in retrospect upon disease relapse, a time when breast cancer is nearly always incurable. Currently, there are few reliable methods to predict the success or failure of a particular postoperative treatment modality, and better ways to predict and optimize outcome are needed. Combination endocrine therapy: Using endocrine agents with different mechanisms of action together has the potential advantage of more effectively blocking ER signaling, thus improving the efficacy of such agents against breast cancer. In the past, attempts to combine endocrine agents for ER-positive breast cancer have had mixed results, depending on the setting and the patient population studied. Endocrine agents without any agonist effect could potentially be used in combination with aromatase inhibitors, under the rationale that the combination would maximally blockade estrogen receptor signaling, thus potential
Interventions
- DRUG Arimidex
- DRUG Faslodex
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2007-12 |
| Est. Completion | 2018-12-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00570323
The ClinicalTrials.gov registry entry for NCT00570323 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mothaffar Rimawi, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Arimidex is the first listed.
NCT00570323 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00570323 about?
NCT00570323 is a clinical study titled "Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer". Over the last 3 decades, a steady shift has occurred in the management of breast cancer. Because it was traditionally viewed as a local disease, many advocated the use of radical surgery to achieve maximum survival benefit. This view has been slowly replaced by a broader biologic view that recognize...
What is the current status of trial NCT00570323?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2007-12. Estimated completion is 2018-12-05.
What interventions are being tested in trial NCT00570323?
The interventions under investigation include: Arimidex (DRUG), Faslodex (DRUG).
Who is sponsoring clinical trial NCT00570323?
This trial is sponsored by Mothaffar Rimawi, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.